Shares of Acorda Therapeutics of Hawthorne, a biomedical company that is testing Fampridine-SR, a drug that could help multiple sclerosis patients walk, increased 164 percent from their February offering price of $6 to yesterday's $15.84 close.
http://www.thejournalnews.com/apps/pbcs.dll/article?AID=/20061230/BUSINESS01/612300333/1066